These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 29002459)

  • 1. The Administration of Antiperiodics & Iron.
    Green CRM
    Ind Med Gaz; 1899 Nov; 34(11):401. PubMed ID: 29002459
    [No Abstract]   [Full Text] [Related]  

  • 2. New Antiperiodics.
    Med Exam (Phila); 1851 Jan; 7(73):69-70. PubMed ID: 38121032
    [No Abstract]   [Full Text] [Related]  

  • 3. Two different modalities of iron gluconate i.v. administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients.
    de Vecchi AF; Novembrino C; Lonati S; Ippolito S; Bamonti F
    Nephrol Dial Transplant; 2007 Jun; 22(6):1709-13. PubMed ID: 17298995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceleration of iron utilization after intravenous iron administration during activated erythropoiesis in hemodialysis patients: a randomized study.
    Kuji T; Toya Y; Fujikawa T; Kakimoto-Shino M; Nishihara M; Shibata K; Tamura K; Hirawa N; Satta H; Kawata S; Kouguchi N; Umemura S
    Ther Apher Dial; 2015 Apr; 19(2):131-7. PubMed ID: 25257861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure.
    Lim CS; Vaziri ND
    Kidney Int; 2004 May; 65(5):1802-9. PubMed ID: 15086920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
    Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients.
    Gelone DK; Park JM; Lake KD
    Pharmacotherapy; 2007 Sep; 27(9):1272-8. PubMed ID: 17723081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral iron administration through drinking water as compared with parenteral administration of iron dextran preparations in piglets].
    Meyer P; Matzke P; Peschke W; Kaufmann G
    Berl Munch Tierarztl Wochenschr; 1975 Nov; 88(21):409-12. PubMed ID: 1200962
    [No Abstract]   [Full Text] [Related]  

  • 11. Postnatal iron-induced motor behaviour alterations following chronic neuroleptic administration in mice.
    Fredriksson A; Eriksson P; Archer T
    J Neural Transm (Vienna); 2006 Feb; 113(2):137-50. PubMed ID: 16082515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of iron deficiency anemia: are monomeric iron compounds suitable for parenteral administration?
    Gupta A; Crumbliss AL
    J Lab Clin Med; 2000 Nov; 136(5):371-8. PubMed ID: 11079464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum iron concentrations following administration of two different iron preparations.
    Danisi M; Guerresi E; Landucci G; Gori G; Ceccarelli G
    J Int Med Res; 1987; 15(6):374-8. PubMed ID: 3436485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of iron supply for erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of iron indices in hemodialysis patients receiving epoetin.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA;
    Kidney Int; 2001 Jul; 60(1):300-8. PubMed ID: 11422765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy.
    Cermák J
    Hemoglobin; 2006; 30(1):105-12. PubMed ID: 16540422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
    Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
    Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there any role of intravenous iron for the treatment of anemia in cancer?
    Gemici C; Yetmen O; Yaprak G; Ozden S; Tepetam H; Ozyurt H; Mayadagli A
    BMC Cancer; 2016 Aug; 16(1):661. PubMed ID: 27542823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe hypophosphataemia after intravenous iron administration.
    Blazevic A; Hunze J; Boots JM
    Neth J Med; 2014 Jan; 72(1):49-53. PubMed ID: 24457442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.